Electric fields with targeted radiation vs. alone for recurrent brain cancer
Part of Cancer clinical trials.
This trial tests whether adding a precise, MRI-guided radiation treatment to tumor-treating electric fields (TTFields) can help people with recurrent glioblastoma. You may qualify if your tumor has come back 1 to 3 times after standard therapy and you haven't had certain prior treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have a type of brain cancer called IDH-wildtype glioblastoma that has returned after treatment.
- Your tumor shows up on an MRI with contrast dye and the largest spot is 5 cm or smaller.
- You finished your last round of radiation at least 6 months ago.
- You have not received the drug bevacizumab before or had certain types of repeat radiation in the same area.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new radiation treatment that targets tumor cells directly. It may help people with a specific type of aggressive brain tumor that has grown after standard treatments.
This trial tests a new type of targeted radiation therapy for people with high-grade glioma (grade 3 or 4) that has not progressed after standard treatment. The therapy uses a radioactive substance attached to a protein that targets tumor cells, aiming to deliver radiation directly to the cancer.
This trial tests whether adding a special type of radiofrequency electromagnetic field treatment to standard chemotherapy and radiation therapy helps people with newly diagnosed glioblastoma. It is for patients who are planning to receive standard treatment and have had surgery to remove the tumor.
This trial looks at how well Tumor Treating Fields (TTFields) therapy works for people with newly diagnosed glioblastoma. Researchers will study blood and tumor samples to find markers that might predict how well the treatment works.
This trial uses a special type of PET scan (FET-PET) to help doctors distinguish between pseudoprogression (a temporary reaction to treatment that can look like tumor growth on MRI) and actual tumor recurrence in people with glioblastoma. The goal is to improve management decisions and avoid unnecessary treatments.
This trial tests whether using advanced MRI scans before radiation therapy can help doctors target the tumor more precisely and possibly improve outcomes for people with glioblastoma. It aims to make radiation treatment more personalized.
Hear when a new Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.